Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking Session Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present additional positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in adult patients with moderate-to-severe chronic hand eczema (CHE) in a late-breaking research program at the American Academy of Dermatology Virtual Meeting (AAD VMX 2021), to be held April 23 – 25, 2021. Details can be found here: https://lnkd.in/ezzTXqM
关于我们
Asana BioSciences, a clinical-stage biopharmaceutical company, was founded in 2014 with the mission to develop novel, clinically differentiated, best-in-class products that address unmet medical needs and provide new treatment options for cancer patients and those suffering from inflammatory conditions. Seven successful INDs were filed in a short span after founding of Asana and multiple clinical proof of concepts studies have been completed in oncology and immunology/inflammation therapeutic categories. Gusacitinib (ASN002), Asana’s lead immunology asset, is entering phase 3 development. Asana’s lead oncology asset (ASN007 or ERAS-007) has completed phase 1 trials in cancer patients. Multiple drugs from Asana’s portfolio have already been out-licensed/partnered with other biotech companies for further development and commercialization.
- 网站
-
https://www.asanabio.com
Asana BioSciences, LLC的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Bridgewater，New Jersey
- 类型
- 私人持股
- 创立
- 2014
- 领域
- oncology、inflammation、pain、atopic dermatitis、drug discovery、clinical development、pruritus和immunology
地点
-
主要
获取路线
400 Crossing Blvd
US，New Jersey，Bridgewater，08807